Cohort | Outcome | Without 14-3-3η | With 14-3-3η | |||
---|---|---|---|---|---|---|
≥0.2 ng/ml | ≥0.4 ng/ml | ≥0.8 ng/ml | ||||
Early RA | Joint damage status | Model LR | 2.99 | 7.06 | 8.54 | 8.54 |
p | 0.084 | 0.029 | 0.014 | 0.014 | ||
R 2 | 0.065 | 0.154 | 0.187 | 0.187 | ||
Radiographic progression | Model LR | 11.16 | 12.27 | 13.72 | 13.72 | |
P | 0.004 | 0.007 | 0.003 | 0.003 | ||
R 2 | 0.252 | 0.273 | 0.310 | 0.310 | ||
Established RA | Joint damage status | Model LR | 12.35 | 13.94 | 12.36 | 12.76 |
P | 0.006 | 0.008 | 0.015 | 0.013 | ||
R 2 | 0.376 | 0.425 | 0.377 | 0.389 | ||
Radiographic progression | Model LR | 8.78 | 9.71 | 13.78 | 13.13 | |
P | 0.003 | 0.008 | 0.001 | 0.001 | ||
R 2 | 0.167 | 0.185 | 0.262 | 0.250 |